These companies are at the cutting edge of drug discovery and biotech innovation, developing breakthrough treatments for cancer, autoimmune disorders, and other complex diseases that could transform healthcare in Brazil.
With substantial operations and partnerships in Brazil, these multinational pharmaceutical leaders are directly shaping the country's health ecosystem and driving access to advanced medicines.
From biologics innovators to essential generic manufacturers, this collection captures the diverse opportunities within one of the world's largest and most dynamic pharmaceutical markets.
Interpretation for 'The Titans of Global Pharmaceuticals in Brazil | A US/EU View' basket based on provided market capitalisation data.
MRK: $210.09B
NVS: $274.48B
SNY: $120.05B
Brazil's pharmaceutical market is one of the largest globally, attracting massive investment from US and European healthcare giants. These multinational companies are driving innovation in drug discovery, biologics, and treatments for complex diseases like cancer and autoimmune disorders, making them essential players in Brazil's health ecosystem.
This group includes diverse pharmaceutical leaders - from cutting-edge biotech innovators to essential generic drug manufacturers serving Brazil's public health system. These companies operate through strategic partnerships, local operations, clinical trials, and substantial sales networks across the country.
These specific companies were handpicked for their substantial operations, partnerships, or sales within Brazil. They represent the multinational giants at the forefront of biotech innovation, offering exposure to the firms shaping the future of medicine in one of the world's most important pharmaceutical markets.
Brazil's large and innovative pharmaceutical market presents a significant area of interest for those looking at global healthcare trends. This basket provides exposure to leading US and EU-listed pharmaceutical and biotech companies with substantial operations, partnerships, or sales within Brazil.
Veröffentlicht am Oktober 16
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
Es dauert nur 60 Sekunden.
Erfahren Sie alles über diesen Aktienkorb. Lesen Sie unseren ausführlichen Artikel zu seinen Risiken und seinem Potenzial.
Vollständige Analyse lesen
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
Wenn Sie in diese Werte investieren:
In 12 Monaten könnte der Wert betragen:
+4.14%
Analysten erwarten im Durchschnitt, dass die Werte dieser Gruppe im nächsten Jahr um 4.14 % zulegen.
3 von 5 Werten dieser Gruppe werden von professionellen Analysten mit „Kaufen“ bewertet.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
